ULTRAGENYX PHARMACEUTICAL INC. Income Tax Expense
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Income Tax Expense of $1.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for the quarter ending 2026-06-30 was $1.00M, a 0.00% change year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for the quarter ending 2026-03-31 was $1.00M, a 0.00% change year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for the quarter ending 2025-12-31 was $870.00K, a 126.56% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for the quarter ending 2025-09-30 was $873.00K, a 188.12% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for fiscal 2025 was $4.00M, a 100.00% increase from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for fiscal 2024 was $2.00M.
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for fiscal 2023 was -$2.00M, a 135.11% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. income tax expense (benefit) for fiscal 2022 was $5.70M, a 445.59% increase from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 6 month as first filed | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00M 10-Q · filed 2026-08-05 | $2.00M 10-Q · filed 2026-08-05 | $2.87M derived: sum of 3 quarters · filed 2026-08-05 | $3.74M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-06 | $1.87M derived: sum of 2 quarters · filed 2026-05-06 | $2.74M derived: sum of 3 quarters · filed 2026-05-06 | $3.74M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $870.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $1.74M derived: sum of 2 quarters · filed 2026-02-18 | $2.74M derived: sum of 3 quarters · filed 2026-08-05 | $4.00M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | $873.00K 10-Q · filed 2025-11-05 | $1.87M derived: sum of 2 quarters · filed 2026-08-05 | $3.13M 10-Q · filed 2025-11-05 | $3.26M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-05 | $947.00K 10-Q · filed 2025-08-06 | $2.00M 10-Q · filed 2026-08-05 | $2.26M 10-Q · filed 2025-08-06 | $2.38M derived: sum of 3 quarters · filed 2026-08-05 | $2.69M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-06 | $1.31M 10-Q · filed 2025-05-07 | $1.38M derived: sum of 2 quarters · filed 2026-05-06 | $1.69M derived: sum of 3 quarters · filed 2026-05-06 | $2.54M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $384.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $687.00K derived: sum of 2 quarters · filed 2026-02-18 | $1.54M derived: sum of 3 quarters · filed 2026-02-18 | $2.00M 10-K · filed 2026-02-18 | $1.60M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $303.00K 10-Q · filed 2025-11-05 | $1.16M derived: sum of 2 quarters · filed 2025-11-05 | $1.62M 10-Q · filed 2025-11-05 | -$2.26M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-06-30 | $858.00K 10-Q · filed 2025-08-06 | $1.31M 10-Q · filed 2025-08-06 | -$2.56M derived: sum of 3 quarters · filed 2026-02-18 | -$1.91M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-03-31 | $455.00K 10-Q · filed 2025-05-07 | -$3.42M derived: sum of 2 quarters · filed 2026-02-18 | -$2.77M derived: sum of 3 quarters · filed 2026-02-18 | -$2.04M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2023-12-31 | -$3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$3.23M derived: sum of 2 quarters · filed 2026-02-18 | -$2.50M derived: sum of 3 quarters · filed 2026-02-18 | -$2.00M 10-K · filed 2026-02-18 | -$1.82M 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $650.00K 10-Q · filed 2024-11-06 | $1.38M derived: sum of 2 quarters · filed 2024-11-06 | $1.88M 10-Q · filed 2024-11-06 | $426.00K derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $732.00K 10-Q · filed 2024-08-02 | $1.23M 10-Q · filed 2024-08-02 | -$224.00K derived: sum of 3 quarters · filed 2025-02-19 | $6.06M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | $495.00K 10-Q · filed 2024-05-03 | -$956.00K derived: sum of 2 quarters · filed 2025-02-19 | $5.33M derived: sum of 3 quarters · filed 2025-02-19 | $5.63M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $4.84M derived: sum of 2 quarters · filed 2025-02-19 | $5.14M derived: sum of 3 quarters · filed 2025-02-19 | $5.70M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $6.29M 10-Q · filed 2023-11-03 | $6.59M derived: sum of 2 quarters · filed 2023-11-03 | $7.15M 10-Q · filed 2023-11-03 | $7.17M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | $302.00K 10-Q · filed 2023-08-04 | $860.00K 10-Q · filed 2023-08-04 | $880.00K derived: sum of 3 quarters · filed 2024-02-21 | $1.06M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | $558.00K 10-Q · filed 2023-05-05 | $578.00K derived: sum of 2 quarters · filed 2024-02-21 | $760.00K derived: sum of 3 quarters · filed 2024-02-21 | $1.22M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $202.00K derived: sum of 2 quarters · filed 2024-02-21 | $665.00K derived: sum of 3 quarters · filed 2024-02-21 | $1.04M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $182.00K 10-Q · filed 2022-11-03 | $645.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.02M 10-Q · filed 2022-11-03 | $1.09M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-06-30 | $463.00K 10-Q · filed 2022-07-29 | $842.00K 10-Q · filed 2022-07-29 | $912.00K derived: sum of 3 quarters · filed 2023-02-17 | $1.23M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-03-31 | $379.00K 10-Q · filed 2022-05-06 | $449.00K derived: sum of 2 quarters · filed 2023-02-17 | $762.00K derived: sum of 3 quarters · filed 2023-02-17 | $1.18M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2020-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $383.00K derived: sum of 2 quarters · filed 2023-02-17 | $798.00K derived: sum of 3 quarters · filed 2023-02-17 | $1.21M 10-K · filed 2023-02-17 | |||
| 2020-09-30 | $313.00K 10-Q · filed 2021-11-03 | $728.00K derived: sum of 2 quarters · filed 2021-11-03 | $1.14M 10-Q · filed 2021-11-03 | $3.70M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-06-30 | $415.00K 10-Q · filed 2021-08-03 | $824.00K 10-Q · filed 2021-08-03 | $3.38M derived: sum of 3 quarters · filed 2022-02-15 | $3.68M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-03-31 | $409.00K 10-Q · filed 2021-05-05 | $2.97M derived: sum of 2 quarters · filed 2022-02-15 | $3.26M derived: sum of 3 quarters · filed 2022-02-15 | $3.48M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2019-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $2.85M derived: sum of 2 quarters · filed 2022-02-15 | $3.07M derived: sum of 3 quarters · filed 2022-02-15 | $3.28M 10-K · filed 2022-02-15 | |||
| 2019-09-30 | $293.00K 10-Q · filed 2020-10-27 | $506.00K derived: sum of 2 quarters · filed 2020-10-27 | $722.00K 10-Q · filed 2020-10-27 | $848.00K derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-06-30 | $213.00K 10-Q · filed 2020-07-30 | $429.00K 10-Q · filed 2020-07-30 | $555.00K derived: sum of 3 quarters · filed 2021-02-12 | $802.00K derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-03-31 | $216.00K 10-Q · filed 2020-05-07 | $342.00K derived: sum of 2 quarters · filed 2021-02-12 | $589.00K derived: sum of 3 quarters · filed 2021-02-12 | $691.00K derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2018-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $373.00K derived: sum of 2 quarters · filed 2021-02-12 | $475.00K derived: sum of 3 quarters · filed 2021-02-12 | $514.00K 10-K · filed 2021-02-12 | |||
| 2018-09-30 | $247.00K 10-Q · filed 2019-11-06 | $349.00K derived: sum of 2 quarters · filed 2019-11-06 | $388.00K 10-Q · filed 2019-11-06 | -$15.83M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2018-06-30 | $102.00K 10-Q · filed 2019-08-02 | $141.00K 10-Q · filed 2019-08-02 | -$16.08M derived: sum of 3 quarters · filed 2020-02-14 | -$16.07M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2018-03-31 | $39.00K 10-Q · filed 2019-05-07 | -$16.18M derived: sum of 2 quarters · filed 2020-02-14 | -$16.17M derived: sum of 3 quarters · filed 2020-02-14 | -$16.16M derived: sum of 4 quarters · filed 2020-02-14 | |||
| 2017-12-31 | -$16.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | -$16.21M derived: sum of 2 quarters · filed 2020-02-14 | -$16.20M derived: sum of 3 quarters · filed 2020-02-14 | -$16.20M 10-K · filed 2020-02-14 | |||
| 2017-09-30 | $4.00K 10-Q · filed 2018-11-06 | $18.00K derived: sum of 2 quarters · filed 2018-11-06 | $18.00K 10-Q · filed 2018-11-06 | ||||
| 2017-06-30 | $14.00K 10-Q · filed 2018-08-03 | $14.00K 10-Q · filed 2018-08-03 | |||||
| 2016-12-31 | $35.00K 10-K · filed 2019-02-20 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2016-02-26 | ||||||
| 2014-12-31 | $0.00 10-K · filed 2016-02-26 | ||||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |